COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia (PREVENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03373435
Recruitment Status : Completed
First Posted : December 14, 2017
Last Update Posted : February 6, 2020
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 19, 2018
Actual Study Completion Date : October 15, 2018
Certification/Extension First Submitted : January 27, 2020